The Immune Tolerance Network (ITN) is an international clinical research consortium sponsored by NIAID, part of the National Institutes of Health. Our mission is to accelerate the clinical development of immune tolerance therapies.
Immune tolerance therapies reprogram the immune system in a highly specific manner so that disease-causing immune responses are stopped while maintaining the immune system’s ability to combat pathogen infection. The ITN develops and conducts clinical trials and mechanistic studies of specialized immune tolerance therapies in the following areas:
- Autoimmune Disease
- Allergies and Asthma
- Organ Transplantation
- Type 1 Diabetes
More than a funding source...
The ITN facilitates collaborative studies between academic, governmental and industry researchers in order to develop and support cutting edge immune tolerance research that could not otherwise be conducted.
The ITN development model is a highly interactive process that capitalizes on our wide-ranging, multidisciplinary expertise, provided by an advisory board of highly respected faculty from institutions world-wide. It begins with the application process - from pre- and post-application support, to formal Q&A sessions with reviewers, we help investigators develop high quality research studies.
More than clinical trials...
The ITN looks beyond the traditional clinical trial endpoints of safety and efficacy, actively investigating the mechanisms of tolerance induction and maintenance, developing clinical trials based upon mechanism-based hypotheses. In addition to clinical efficacy, ITN clinical trials validate tolerance mechanisms while also defining new biomarkers of tolerance in human disease. Supported by an unprecedented array of core facilities offering state-of-the-art genetic, cellular and immunologic assays, the ITN is generating some of the first combined clinical and mechanistic data on immune tolerance induction in humans.
ITN by the numbers...
Active in 10 countries with ITN sites or members
• 48 clinical trials - 9 Allergy trials; 23 Autoimmunity trials; 16 Transplant trials
• 178 clinical sites and investigators at leading academic hospitals worldwide
• 3000+ patients enrolled in ITN clinical trials
• 100+ tolerant patients off of all immunosuppression to date
• 16 core labs performing standardized routine and specialized assays
• 68 Full time employees plus a steering committee of 30 physicians and scientists
• 108 peer-reviewed publications in top-tier biomedical journals
• 177 meeting abstracts presented at national and international meetings
• 375,000 clinical specimens in the ITN repository